Clinical data | |
---|---|
Trade names | Fluothane |
AHFS/Drugs.com | FDA Professional Drug Information |
License data | |
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Hepatic (CYP2E1[4]) |
Excretion | Kidney, respiratory |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.270 |
Chemical and physical data | |
Formula | C2HBrClF3 |
Molar mass | 197.38 g·mol−1 |
3D model (JSmol) | |
Density | 1.871 g/cm3 (at 20 °C) |
Melting point | −118 °C (−180 °F) |
Boiling point | 50.2 °C (122.4 °F) |
| |
| |
(verify) |
Halothane, sold under the brand name Fluothane among others, is a general anaesthetic.[5] It can be used to induce or maintain anaesthesia.[5] One of its benefits is that it does not increase the production of saliva, which can be particularly useful in those who are difficult to intubate.[5] It is given by inhalation.[5]
Side effects include an irregular heartbeat, respiratory depression, and hepatotoxicity.[5] Like all volatile anesthetics, it should not be used in people with a personal or family history of malignant hyperthermia.[5] It appears to be safe in porphyria.[6] It is unclear whether its usage during pregnancy is harmful to the fetus, and its use during a C-section is generally discouraged.[7] Halothane is a chiral molecule that is used as a racemic mixture.[8]
Halothane was discovered in 1951.[9] It was approved for medical use in the United States in 1958.[3] It is on the World Health Organization's List of Essential Medicines.[10] Its use in developed countries has been mostly replaced by newer anesthetic agents such as sevoflurane.[11] It is no longer commercially available in the United States.[7] Halothane also contributes to ozone depletion.[12][13]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search